Trial reportNature2020
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Erratum issued 2 registry-linked trialsAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 900 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
900citing papers in PubMed, 5 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines
Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities
Who cites it
900 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Vaccines for preventing infections in adults with haematological malignancies.The Cochrane database of systematic reviews · 2025Pooled it
- Vaccines for preventing infections in adults with solid tumours.The Cochrane database of systematic reviews · 2025Pooled it
- Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review.Molecular biotechnology · 2024Pooled it
- Serious neurological adverse events in immunocompetent children and adolescents caused by viral reactivation in the years following varicella vaccination.Reviews in medical virology · 2024Pooled it
- Pooled it
- Safety, immunogenicity, persistence and dose evaluation of the CS-2034 mRNA COVID-19 vaccine: a phase II randomized controlled trial in healthy Chinese adults.BMC infectious diseases · 2025Trial
- Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers.Nature communications · 2025Trial
- SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.The Lancet. Microbe · 2024Trial
- Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.BMJ (Clinical research ed.) · 2023Trial
- Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.Scientific reports · 2023Trial
- Trial
- Chimeric SARS-CoV-2 vaccine vectors stably incorporating the functional glycoprotein of VSV.iScience · 2026Article
- Effects of natural killer cell depletion on innate and adaptive immune responses to COVID mRNA vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Article
- A dimeric mRNA vaccine based on key-mutant and KP.3 RBDs induces broad-spectrum immunity and protects mice against JN.1 and XDV challenges.Molecular biomedicine · 2026Article
- pH-Sensitive Amino Lipid-Driven Pore Formation Enables Endosomal Escape of Lipid Nanoparticles.Nature communications · 2026Article
- Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Article
- Spatiotemporal distribution of SARS-CoV-2 vaccines and vaccine-related proteins in mice and humans.Scientific reports · 2026Article
- GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.Drug safety · 2026Article
840 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
25 authors.
Mark J Mulligan *New York University Langone Vaccine Center, New York, NY, USA.
Kirsten E Lyke *University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD, USA.
Nicholas Kitchin *Vaccine Research and Development, Pfizer Inc, Hurley, UK.
Judith AbsalonVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA. judith.absalon@pfizer.com.ORCID http://orcid.org/0000-0002-1091-520X
Alejandra GurtmanVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
Stephen LockhartVaccine Research and Development, Pfizer Inc, Hurley, UK.
Kathleen NeuzilUniversity of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD, USA.
Vanessa RaabeNew York University Langone Vaccine Center, New York, NY, USA.
Ruth BaileyVaccine Research and Development, Pfizer Inc, Hurley, UK.
Kena A SwansonVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.ORCID http://orcid.org/0000-0002-3389-8414
Ping LiVaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.
Kenneth KouryVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
Warren KalinaVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
David CooperVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
Camila Fontes-GarfiasUniversity of Texas Medical Branch, Galveston, TX, USA.
Pei-Yong ShiUniversity of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0001-5553-1616
Özlem TüreciBioNTech, Mainz, Germany.
Kristin R TompkinsVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
Edward E WalshUniversity of Rochester, Rochester, NY, USA.
Robert FrenckCincinnati Children's Hospital, Cincinnati, OH, USA.
Ann R FalseyUniversity of Rochester, Rochester, NY, USA.
Philip R DormitzerVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
William C GruberVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
Uğur ŞahinBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0003-0363-1564
Kathrin U JansenVaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Indexed as
AdultAntibodies, NeutralizingAntibodies, ViralCoronavirus InfectionsCOVID-19COVID-19 SerotherapyCOVID-19 VaccinesFemaleHumansImmunization, PassiveImmunoglobulin GMaleMiddle AgedPandemicsPneumonia, ViralSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Vaccines
Identifiers
PMID
32785213What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04775069ClinicalTrials.gov
NCT04944095ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.